RxDoctor Payments Data

Liana Volpe, MD

General Practice · Sun Valley, CANPI 1154366730

Payments from drug & device makers

$211in general payments, 2019–2025

Across 6 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$125
  • AstraZeneca$24
  • Sunovion Pharmaceuticals Inc.$19
  • Sun Pharmaceutical Industries Inc.$18
  • Bayer$14
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211 in reported general payments places this provider in the 45th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$297,944
Medicare patients
236
Services billed
1,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate75$78,385
EliquisApixaban167$66,882
XareltoRivaroxaban91$59,888
GlatopaGlatiramer Acetate13$35,170
JardianceEmpagliflozin34$21,249
TradjentaLinagliptin44$19,360
RybelsusSemaglutide12$17,223
OzempicSemaglutide13$15,288
LinzessLinaclotide21$13,344
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$12,781
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$7,442
Pantoprazole Sodium115$6,098
Diflorasone Diacetate12$5,843
Famotidine131$5,450
Divalproex Sodium72$4,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$11$32,51125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 12,963 general practice providers in California.

Other general practice in Sun Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →